DXCM - DexCom, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
San Diego,
United States
Type: Equity
DXCM price evolution
DXCM
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $939.2 | $851.2 | $566.3 | |
| Short term investments | $2181.5 | $2045.8 | $2157.8 | |
| Net receivables | $1033.7 | $945.2 | $978.6 | $973.9 |
| Inventory | $586.3 | $570.3 | $589.1 | $559.6 |
| Total current assets | $4262.8 | $4848.4 | $4620.7 | $4425.9 |
| Long term investments | ||||
| Property, plant & equipment | $1386.3 | $1254.3 | $1176.6 | $1184.5 |
| Goodwill & intangible assets | $137.8 | $146.5 | $159.7 | |
| Total noncurrent assets | $1950.8 | $1861.5 | $1838.6 | |
| Total investments | $2181.5 | $2045.8 | $2157.8 | |
| Total assets | $6353.8 | $6799.2 | $6482.2 | $6264.5 |
| Current liabilities | ||||
| Accounts payable | $326.6 | $1569.8 | $1446.6 | $1345.5 |
| Deferred revenue | $14.7 | $16.4 | $18.4 | |
| Short long term debt | $21.6 | $20.7 | $21.1 | |
| Total current liabilities | $1734.5 | $1722.2 | $1594.2 | $1556 |
| Long term debt | $2497.8 | $2514.6 | $2511.8 | $2514.3 |
| Total noncurrent liabilities | $2642.7 | $2641.2 | $2639.9 | |
| Total debt | $2536.2 | $2532.5 | $2535.4 | |
| Total liabilities | $4374.8 | $4364.9 | $4235.4 | $4195.9 |
| Shareholders' equity | ||||
| Retained earnings | $1445.9 | $1311.3 | $1167.8 | $1021.4 |
| Other shareholder equity | $63.4 | -$38 | -$37.3 | -$16.7 |
| Total shareholder equity | $2434.3 | $2246.8 | $2068.6 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $566.3 | $642.3 | $1052.6 | $817.6 |
| Short term investments | $2157.8 | $1813.9 | $1678.6 | $1890.1 |
| Net receivables | $973.9 | $713.3 | $514.3 | $428.5 |
| Inventory | $559.6 | $306.7 | $357.3 | $234.7 |
| Total current assets | $4425.9 | $3668.8 | $3684.4 | $3424.8 |
| Long term investments | ||||
| Property, plant & equipment | $1184.5 | $1135.6 | $889.9 | $608.6 |
| Goodwill & intangible assets | $159.7 | $199 | $68.5 | $19.3 |
| Total noncurrent assets | $1838.6 | $1722.9 | $1179.2 | $865.7 |
| Total investments | $2157.8 | $1813.9 | $1678.6 | $1890.1 |
| Total assets | $6264.5 | $5391.7 | $4863.6 | $4290.5 |
| Current liabilities | ||||
| Accounts payable | $1345.5 | $237.9 | $573 | $481.1 |
| Deferred revenue | $18.4 | $10.1 | $2.1 | $2.2 |
| Short long term debt | $21.1 | $793.1 | $20.5 | $16.5 |
| Total current liabilities | $1556 | $1839.3 | $720.8 | $614.1 |
| Long term debt | $2514.3 | $1257.3 | $1801.3 | $1769 |
| Total noncurrent liabilities | $2639.9 | $1420.6 | $1891.3 | $1849.9 |
| Total debt | $2535.4 | $2085.4 | $1821.8 | $1785.5 |
| Total liabilities | $4195.9 | $3259.9 | $2612.1 | $2464 |
| Shareholders' equity | ||||
| Retained earnings | $1021.4 | $479.9 | -$47.4 | -$202.1 |
| Other shareholder equity | -$16.7 | -$11.6 | $0.5 | $3.2 |
| Total shareholder equity | $2068.6 | $2131.8 | $2251.5 | $1826.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $994.2 | $1004.3 | $921 | $1034.5 |
| Cost of revenue | $377.6 | $359.1 | $377.9 | |
| Gross Profit | $593.8 | $626.7 | $561.9 | $656.6 |
| Operating activities | ||||
| Research & development | $136 | $141.5 | $136.1 | |
| Selling, general & administrative | $332.7 | $319.3 | $308.8 | |
| Total operating expenses | $441.8 | $468.7 | $460.8 | $439.7 |
| Operating income | $158 | $101.1 | $216.9 | |
| Income from continuing operations | ||||
| EBIT | $187.8 | $132.5 | $251.1 | |
| Income tax expense | $42.8 | $44.3 | -$13.9 | -$10.1 |
| Interest expense | $27.3 | $4.9 | ||
| Net income | ||||
| Net income | $134.6 | $143.5 | $146.4 | $256.3 |
| Income (for common shares) | $143.5 | $146.4 | $256.3 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3622.3 | $2909.8 | $2448.5 | $1926.7 |
| Cost of revenue | $1333.4 | $1026.7 | $768 | $646.6 |
| Gross Profit | $2288.9 | $1883.1 | $1680.5 | $1280.1 |
| Operating activities | ||||
| Research & development | $505.8 | $484.2 | $517.1 | $359.9 |
| Selling, general & administrative | $1185.4 | $1000.2 | $810.5 | $620.7 |
| Total operating expenses | $1691.2 | $1491.9 | $1414.7 | $980.6 |
| Operating income | $597.7 | $391.2 | $265.8 | $299.5 |
| Income from continuing operations | ||||
| EBIT | $730.7 | $391.4 | $275.9 | $309.7 |
| Income tax expense | $168.9 | $49.6 | $19.2 | -$268.6 |
| Interest expense | $20.3 | $0.6 | $102 | $84.7 |
| Net income | ||||
| Net income | $541.5 | $341.2 | $154.7 | $493.6 |
| Income (for common shares) | $541.5 | $341.2 | $154.7 | $493.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $143.5 | $146.4 | $256.3 | |
| Operating activities | ||||
| Depreciation | $52.1 | $52.5 | $52.5 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $44.7 | $39 | $36.9 | |
| Total cash flows from operations | $279.4 | $209.2 | $133.6 | |
| Investing activities | ||||
| Capital expenditures | -$66.1 | -$56.9 | -$52.5 | |
| Investments | -$117.4 | $129.4 | $466.5 | |
| Total cash flows from investing | $96.2 | -$188.9 | $74.8 | $414.9 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $13.4 | -$500 | ||
| Net borrowings | -$136.8 | |||
| Total cash flows from financing | -$733.2 | -$1.4 | $4.7 | -$631.9 |
| Effect of exchange rate | $3.8 | -$1 | -$3.8 | $6.1 |
| Change in cash and equivalents | $54.9 | $88.1 | $284.9 | -$77.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $541.5 | $341.2 | $154.7 | $493.6 |
| Operating activities | ||||
| Depreciation | $186 | $155.9 | $102 | $67.1 |
| Business acquisitions & disposals | -$3.9 | -$30.2 | ||
| Stock-based compensation | $150.8 | $126.5 | $113.4 | $119.4 |
| Total cash flows from operations | $748.5 | $669.5 | $442.5 | $475.6 |
| Investing activities | ||||
| Capital expenditures | -$236.6 | -$364.8 | -$389.2 | -$199 |
| Investments | -$253 | -$138.5 | $193.2 | -$807.7 |
| Total cash flows from investing | -$507.2 | -$521.5 | -$216.1 | -$1018 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$662.1 | -$535.2 | $20.3 | $15.3 |
| Net borrowings | $443.3 | $906.2 | ||
| Total cash flows from financing | -$318.6 | -$552.5 | $10.4 | $912.1 |
| Effect of exchange rate | $1.5 | -$5.8 | -$1.4 | $2.1 |
| Change in cash and equivalents | -$75.8 | -$410.3 | $235.4 | $371.8 |
News
Fundamentals
| Market cap | $26.64B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 390.60M |
| Revenue | $3.95B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $680.80M |
| Revenue Q/Q | 1.97% |
| Revenue Y/Y | 16.19% |
| P/E ratio | 39.13 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.74 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.74 |
|---|---|
| ROA | 10.51% |
| ROE | N/A |
| Debt/Equity | 2.03 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.46 |
| Quick ratio | 2.12 |